Clinical trial
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic…
NCT00381004 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00381004 |
|---|---|
| Title | FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia |
| Official title | Fludarabine, Cyclophosphamide, and Rituximab (FCR) Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Cyclophosphamide, Fludarabine, Sargramostim, Rituximab |
| Enrollment | 60 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2014 |
| Completion | Dec 1, 2014 |
| First posted | Sep 27, 2006 |
| Last update posted | Jan 14, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: